Mohamed Khan

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. ncbi In vivo biodistribution of dendrimers and dendrimer nanocomposites -- implications for cancer imaging and therapy
    Mohamed K Khan
    NanoBiotechnology Center at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Technol Cancer Res Treat 4:603-13. 2005
  2. ncbi Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma
    Mohamed K Khan
    Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Arch Otolaryngol Head Neck Surg 132:333-8. 2006
  3. ncbi Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head
    Susan A McCloskey
    Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Am J Clin Oncol 32:587-91. 2009
  4. ncbi Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models
    Lajos Balogh
    The NanoBiotechnology Center at Roswell Park Cancer Institute NBC at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Nanomedicine 3:281-96. 2007
  5. ncbi Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting alphavbeta3 integrins
    Wojciech G Lesniak
    NanoBiotechnology Center at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Bioconjug Chem 18:1148-54. 2007
  6. ncbi Fabrication of {198Au0} radioactive composite nanodevices and their use for nanobrachytherapy
    Mohamed K Khan
    NanoBiotechnology Center at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Nanomedicine 4:57-69. 2008
  7. ncbi Radiotherapy and antiangiogenic TM in lung cancer
    Mohamed K Khan
    Department of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    Neoplasia 4:164-70. 2002
  8. ncbi Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer
    Jolanta F Kukowska-Latallo
    University of Michigan Center for Biologic Nanotechnology, Ann Arbor, Michigan, USA
    Cancer Res 65:5317-24. 2005
  9. ncbi E-selectin is required for the antiangiogenic activity of endostatin
    Ying Yu
    Vascular Biology Program, Department of Surgery, Children s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:8005-10. 2004
  10. ncbi Tetrathiomolybdate blocks bFGF- but not VEGF-induced incipient angiogenesis in vitro
    Fatema Mamou
    Department of Radiation Oncology, Comprehensive Cancer and Geriatrics Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Anticancer Res 26:1753-8. 2006

Research Grants

  1. Anti-angiogenic Tetrathiomolybdate +XRT in NSCLC-Phase 1
    Mohamed Khan; Fiscal Year: 2004
  2. Imaging Nanocomposites Targeting Tumor Microvasculature
    Mohamed Khan; Fiscal Year: 2007

Collaborators

  • George Brewer
  • Lajos P Balogh
  • Thom R Loree
  • Anurag K Singh
  • Nestor R Rigual
  • T N Teknos
  • KAREN SIMPSON MOULTON
  • Susan A McCloskey
  • Wojciech G Lesniak
  • Muhammed S T Kariapper
  • Bindu M Nair
  • Fatema Mamou
  • Jolanta F Kukowska-Latallo
  • Ying Yu
  • Wesley L Hicks
  • Terry L Mashtare
  • Maureen Sullivan
  • Wainwright Jaggernauth
  • Saurin R Popat
  • Wei Tan
  • Alan Hutson
  • Navkiranjit Gill
  • Daniel Normolle
  • Matthew J Schipper
  • Kerstin S May
  • Istvan J Majoros
  • James R Baker
  • Kimberly A Candido
  • Zhengyi Cao
  • Shraddha S Nigavekar
  • Thommey P Thomas
  • Sabrina Vineberg
  • Eileen Boye
  • David S Milstone
  • Vannessa M Davis
  • Peter E O'Donnell
  • Joyce Bischoff

Detail Information

Publications10

  1. ncbi In vivo biodistribution of dendrimers and dendrimer nanocomposites -- implications for cancer imaging and therapy
    Mohamed K Khan
    NanoBiotechnology Center at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Technol Cancer Res Treat 4:603-13. 2005
    ..We also discuss major issues confronting the use of nanoparticles in the near future, with consideration of toxicity analysis and whether biodegradable devices are needed or even desirable...
  2. ncbi Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma
    Mohamed K Khan
    Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Arch Otolaryngol Head Neck Surg 132:333-8. 2006
    ..To assess the effect of combining tetrathiomolybdate therapy and radiation treatment (RT) on tumor growth in the mouse head and neck squamous cell carcinoma (HNSCC) model...
  3. ncbi Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head
    Susan A McCloskey
    Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Am J Clin Oncol 32:587-91. 2009
    ....
  4. ncbi Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models
    Lajos Balogh
    The NanoBiotechnology Center at Roswell Park Cancer Institute NBC at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Nanomedicine 3:281-96. 2007
    ..These findings have significance for the design of all particle-based nanodevices for medical uses. The observed organ selectivity may make these nanodevices exciting for several targeted medical applications...
  5. ncbi Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting alphavbeta3 integrins
    Wojciech G Lesniak
    NanoBiotechnology Center at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Bioconjug Chem 18:1148-54. 2007
    ..The PAMAM_E5.(NHAc)72(NHBT)8(NHSAH)35(NHSA-cR GD)4 nanodevice is nontoxic within physiologic concentration ranges and specifically binds to the alphavbeta3 integrins, apparently much stronger than the cyclic cRGD peptide itself...
  6. ncbi Fabrication of {198Au0} radioactive composite nanodevices and their use for nanobrachytherapy
    Mohamed K Khan
    NanoBiotechnology Center at RPCI, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Nanomedicine 4:57-69. 2008
    ..No clinical toxicity was observed during the experiments. This study provides the first proof of principle that radioactive CNDs can deliver therapeutic doses to tumors...
  7. ncbi Radiotherapy and antiangiogenic TM in lung cancer
    Mohamed K Khan
    Department of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    Neoplasia 4:164-70. 2002
    ..We also show that their therapeutic effects are additive, with no additional toxicity. We show that TM has no significant cytotoxicity in vitro against LLHM tumor cells, further supporting the antiangiogenic mechanism for its action...
  8. ncbi Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer
    Jolanta F Kukowska-Latallo
    University of Michigan Center for Biologic Nanotechnology, Ann Arbor, Michigan, USA
    Cancer Res 65:5317-24. 2005
    ..Targeting methotrexate increased its antitumor activity and markedly decreased its toxicity, allowing therapeutic responses not possible with a free drug...
  9. ncbi E-selectin is required for the antiangiogenic activity of endostatin
    Ying Yu
    Vascular Biology Program, Department of Surgery, Children s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:8005-10. 2004
    ..E-selectin may be a useful predictor and modulator of endostatin efficacy in antiangiogenic therapy...
  10. ncbi Tetrathiomolybdate blocks bFGF- but not VEGF-induced incipient angiogenesis in vitro
    Fatema Mamou
    Department of Radiation Oncology, Comprehensive Cancer and Geriatrics Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Anticancer Res 26:1753-8. 2006
    ..CONCLUSION: This model permitted the separation of VEGF- and bFGF- induced early angiogenesis in vitro, and indicated the existence of mechanistic differences between bFGF- and VEGF- induced early angiogenic events...

Research Grants6

  1. Anti-angiogenic Tetrathiomolybdate +XRT in NSCLC-Phase 1
    Mohamed Khan; Fiscal Year: 2004
    ..Chest CT and Chest x-ray will be taken to record tumor response, and to compare with 99mTc-MIBI scans. ..
  2. Imaging Nanocomposites Targeting Tumor Microvasculature
    Mohamed Khan; Fiscal Year: 2007
    ..3) intracellular, intratumoral, and whole animal imaging will be accomplished via Transmission Electron Micrography (TEM), an autoradiography and immunohistochemical method, and SPECT imaging respectively. ..